| DENGUE ESSENTIALS: |
| Based on Center for Disease Control (CDC) Website |
| Document Date: February 13, 1998 |
| Print Date: August 19, 2000 |
| Dengue is characterized by sudden onset, high fever,
severe headache, joint and muscle pain and rash. Nausea
and vomiting, loss of appetite, and altered taste
sensation are common. A rash may appear 3 to 4 days after
onset of fever and may spread from the torso to the arms,
legs, and face. The disease is usually benign and
self-limiting after about 7 days. Dengue may also present
as a severe and fatal hemorrhagic disease, called dengue
hemorrhagic fever (DHF). There is no specific
treatment for dengue infection. TRAVELERS SHOULD ADVISE THEIR PHYSICIAN OF ANY ACUTE ILLNESS WITH FEVER OCCURRING WITHIN 3 WEEKS AFTER LEAVING A TROPICAL AREA Aedes Mosquito Dengue is a viral disease transmitted by urban Aedes mosquitos. The principal vector mosquito is Aedes aegypti, a species found living in close association with humans in most tropical urban areas. Mosquito biting activity is greatest in the morning for several hours after daybreak and in the late afternoon for several hours before dark. It may feed all day indoors, in shady areas, or when it is overcast. This mosquito breeds in artificial water containers, such as discarded tires, cans, barrels, buckets, 55 gallon drums, flower vases, and cisterns, all frequently found in the domestic environment. Since 1980, the incidence of dengue has increased dramatically in tropical countries worldwide, with endemic and/or epidemic virus transmission documented in most countries of the Caribbean Basin, Central and South America, the Pacific Islands, Asia, and Africa; many countries have had multiple outbreaks. Epidemics are frequently not reported because of inadequate disease surveillance.
Virus types and distributionThere are four dengue virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), and all are currently circulating in the Pacific Islands, Americas, Asia, and Africa. In the Americas, all but DEN-3 have widespread distribution. DEN-3 was only recently (October 1994) reintroduced into Central America and is now spreading throughout the region. Since this serotype has been absent from the region for 18 years, there is a low level of immunity and rapid spread is expected.
Risk to the TravelerThe risk of dengue infection for the international traveler appears to be small, unless an epidemic is currently in progress. Current data suggest that the strain of dengue virus, and the age, immune status, and genetic background of the human host are important risk factors for developing DHF. In Asia, children under the age of 15 years who are experiencing a second dengue infection appear to have the highest risk of developing DHF. This suggests that most international travelers from nonendemic areas, such as the United States, have a low risk of developing DHF.
Protection against DengueNo vaccine is available for dengue, but travelers can protect themselves by using anti-mosquito measures to avoid being bitten.
General recommendations to avoid mosquito bites:
Note: Vitamin B and ultrasound devices are NOT effective in preventing mosquito bites.
Reduce Your Risk for InfectionYour risk for becoming infected with dengue is lower if you:
Think You Have Dengue?
|